modafinil has been researched along with Apnea, Obstructive Sleep in 62 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
Excerpt | Relevance | Reference |
---|---|---|
"In 2010 the European Medicines Agency withdrew the indication of modafinil for the treatment of obstructive sleep apnea, shift work sleep disorder and for idiopathic hypersomnia (IH)." | 9.20 | Modafinil in the treatment of idiopathic hypersomnia without long sleep time--a randomized, double-blind, placebo-controlled study. ( Benes, H; Bitterlich, M; Mayer, G; Rodenbeck, A; Young, P, 2015) |
"We aimed to evaluate the efficacy of the selective H3 receptor inverse agonist MK-0249 to treat excessive daytime sleepiness (EDS)." | 9.17 | Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study. ( Ceesay, P; Herring, WJ; Hutzelmann, J; Lines, C; Liu, K; Michelson, D; Roth, T; Snavely, D; Snyder, E, 2013) |
"Once-daily modafinil was effective and well tolerated for managing residual daytime sleepiness in Japanese OSAS patients with residual excessive daytime sleepiness on optimal nCPAP therapy." | 9.17 | Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study. ( Inoue, Y; Takasaki, Y; Yamashiro, Y, 2013) |
"Armodafinil-naïve, adult patients with excessive sleepiness associated with treated OSA (n = 170), SWD (n = 108), or narcolepsy (n = 50) received armodafinil (100-250 mg) once daily (treated OSA or narcolepsy) or before night shifts (SWD)." | 9.14 | Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month, open-label, flexible-dose study with an extension period. ( Khan, A; McCall, WV; Schwartz, JR; Tiller, J; Weintraub, J, 2010) |
"Patients with ES associated with treated OSA, SWD, or narcolepsy who completed one of four 12-week, double-blind studies were eligible for this multicenter, open-label study of > or = 12 months' duration of treatment with armodafinil (50 to 250 mg/day)." | 9.14 | The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study. ( Black, JE; Harsh, JR; Hull, SG; Tiller, J; Yang, R, 2010) |
"The results of this indirect treatment comparison show 12 weeks of treatment with solriamfetol, modafinil, and armodafinil resulted in varying levels of improvement on the ESS, MWT20, and CGI-C and similar safety risks in participants with excessive daytime sleepiness associated with obstructive sleep apnea." | 9.12 | Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea. ( Bron, M; Bujanover, S; Kratochvil, D; Lucas, E; Menno, D; Patel, D; Ronnebaum, S; Stepnowsky, C, 2021) |
"Modafinil (Provigil) is approved for treating excessive daytime sleepiness associated with narcolepsy, for shift-work sleep disorder, and as an adjunctive treatment in patients with obstructive sleep apnea syndrome who have residual daytime sleepiness despite optimal treatment with continuous positive airway pressure." | 8.84 | Modafinil in the treatment of excessive daytime sleepiness. ( Foldvary-Schaefer, N; Valentino, RM, 2007) |
"Modafinil is a wake-promoting drug licensed to treat residual sleepiness in CPAP-treated OSA." | 6.79 | Modafinil improves daytime sleepiness in patients with mild to moderate obstructive sleep apnoea not using standard treatments: a randomised placebo-controlled crossover trial. ( Chang, CL; Chapman, JL; Grunstein, RR; Kempler, L; Marshall, NS; Sivam, S; Williams, SC; Wong, KK; Yee, BJ, 2014) |
"Solriamfetol, armodafinil-modafinil, and pitolisant reduce daytime sleepiness for patients with OSA already on conventional therapy, with solriamfetol likely superior." | 5.41 | Comparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea : A Systematic Review and Network Meta-analysis. ( Busse, JW; Desai, K; Gu, Y; Mah, J; Pitre, T; Roberts, S; Ryan, C; Zeraatkar, D, 2023) |
"In 2010 the European Medicines Agency withdrew the indication of modafinil for the treatment of obstructive sleep apnea, shift work sleep disorder and for idiopathic hypersomnia (IH)." | 5.20 | Modafinil in the treatment of idiopathic hypersomnia without long sleep time--a randomized, double-blind, placebo-controlled study. ( Benes, H; Bitterlich, M; Mayer, G; Rodenbeck, A; Young, P, 2015) |
"We aimed to evaluate the efficacy of the selective H3 receptor inverse agonist MK-0249 to treat excessive daytime sleepiness (EDS)." | 5.17 | Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study. ( Ceesay, P; Herring, WJ; Hutzelmann, J; Lines, C; Liu, K; Michelson, D; Roth, T; Snavely, D; Snyder, E, 2013) |
"Once-daily modafinil was effective and well tolerated for managing residual daytime sleepiness in Japanese OSAS patients with residual excessive daytime sleepiness on optimal nCPAP therapy." | 5.17 | Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study. ( Inoue, Y; Takasaki, Y; Yamashiro, Y, 2013) |
"Sodium oxybate (SXB) is approved for cataplexy and excessive daytime sleepiness in narcolepsy." | 5.15 | A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome. ( Feldman, N; George, CF; Grzeschik, SM; Inhaber, N; Lai, C; Steininger, TL; Zheng, Y, 2011) |
"Armodafinil-naïve, adult patients with excessive sleepiness associated with treated OSA (n = 170), SWD (n = 108), or narcolepsy (n = 50) received armodafinil (100-250 mg) once daily (treated OSA or narcolepsy) or before night shifts (SWD)." | 5.14 | Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month, open-label, flexible-dose study with an extension period. ( Khan, A; McCall, WV; Schwartz, JR; Tiller, J; Weintraub, J, 2010) |
"Sodium oxybate (SXB) is an approved drug for the treatment of excessive daytime sleepiness (EDS) and cataplexy in narcolepsy." | 5.14 | A safety trial of sodium oxybate in patients with obstructive sleep apnea: Acute effects on sleep-disordered breathing. ( Feldman, N; George, CF; Grzeschik, SM; Inhaber, N; Lai, C; Steininger, TL; Zheng, Y, 2010) |
"Prospective evaluation of unselected traumatic brain injury patients with nocturnal polysomnography (NPSG), multiple sleep latency test (MSLT), Epworth Sleepiness Scale (ESS), and neuropsychological testing including Psychomotor Vigilance Test (PVT), Profile of Mood States (POMS), and Functional Outcome of Sleep Questionnaire (FOSQ) before and after treatment with continuous positive airway pressure (CPAP) for obstructive sleep apnea (OSA), modafinil (200 mg) for narcolepsy and posttraumatic hypersomnia (PTH), or pramipexole (0." | 5.14 | Treatment of sleep disorders after traumatic brain injury. ( Atanasov, S; Castriotta, RJ; Kuna, ST; Lai, JM; Masel, BE; Wilde, MC, 2009) |
"Patients with ES associated with treated OSA, SWD, or narcolepsy who completed one of four 12-week, double-blind studies were eligible for this multicenter, open-label study of > or = 12 months' duration of treatment with armodafinil (50 to 250 mg/day)." | 5.14 | The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study. ( Black, JE; Harsh, JR; Hull, SG; Tiller, J; Yang, R, 2010) |
"In summary, our study confirms that modafinil used adjunctively with CPAP therapy improves subjective daytime sleepiness in patients with OSAS who were regular users of CPAP therapy but still experienced sleepiness." | 5.13 | Placebo and modafinil effect on sleepiness in obstructive sleep apnea. ( Bittencourt, LR; Garbuio, SA; Guilleminault, C; Lucchesi, LM; Palombini, LO; Rueda, AD; Tufik, S, 2008) |
"The results of this indirect treatment comparison show 12 weeks of treatment with solriamfetol, modafinil, and armodafinil resulted in varying levels of improvement on the ESS, MWT20, and CGI-C and similar safety risks in participants with excessive daytime sleepiness associated with obstructive sleep apnea." | 5.12 | Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea. ( Bron, M; Bujanover, S; Kratochvil, D; Lucas, E; Menno, D; Patel, D; Ronnebaum, S; Stepnowsky, C, 2021) |
"Modafinil (Provigil) is approved for treating excessive daytime sleepiness associated with narcolepsy, for shift-work sleep disorder, and as an adjunctive treatment in patients with obstructive sleep apnea syndrome who have residual daytime sleepiness despite optimal treatment with continuous positive airway pressure." | 4.84 | Modafinil in the treatment of excessive daytime sleepiness. ( Foldvary-Schaefer, N; Valentino, RM, 2007) |
"Armodafinil is a wake-promoting agent developed by Cephalon that was approved in mid-2007 for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work disorder." | 4.84 | Armodafinil: a new treatment for excessive sleepiness. ( Lankford, DA, 2008) |
" Treatment with continuous positive airway pressure (CPAP) for OSA, non-invasive ventilation (NIV) for respiratory failure, modafinil for excessive daytime sleepiness were commenced." | 3.83 | Sleepiness and Sleep-related Breathing Disorders in Myotonic Dystrophy and Responses to Treatment: A Prospective Cohort Study. ( Anderson, KN; Atalaia, A; Baudouin, SV; Hughes, J; Lochmüller, H; Marini-Bettolo, C; West, SD, 2016) |
"Excessive daytime sleepiness (EDS) is a common consequence of OSA and is associated with cognitive deficits and anxiety." | 3.30 | Solriamfetol enhances wakefulness and improves cognition and anxiety in a murine model of OSA. ( Badran, M; Barrow, MB; Gozal, D; Puech, C; Runion, AR, 2023) |
"102 patients with the diagnosis of obstructive sleep apnea (OSA) were randomized to receive either 200 mg of modafinil or placebo before general anesthesia." | 2.87 | A double blind randomized placebo controlled pilot study of single-dose preoperative modafinil for functional recovery after general anesthesia in patients with obstructive sleep apnea. ( Carr, ZJ; Karamchandani, K; Kunselman, AA; Lowery, JD; Rogers, AM; Vaida, SJ; Vells, B; Wood, BR, 2018) |
"Armodafinil was generally well tolerated." | 2.79 | Effect of armodafinil on cortical activity and working memory in patients with residual excessive sleepiness associated with CPAP-Treated OSA: a multicenter fMRI study. ( Diaz, MT; Drummond, SP; Duntley, SP; Greve, DN; Krystal, AD; Kushida, CA; Larson-Prior, L; Thein, SG; Thomas, RJ; Yang, R, 2014) |
"Modafinil is a wake-promoting drug licensed to treat residual sleepiness in CPAP-treated OSA." | 2.79 | Modafinil improves daytime sleepiness in patients with mild to moderate obstructive sleep apnoea not using standard treatments: a randomised placebo-controlled crossover trial. ( Chang, CL; Chapman, JL; Grunstein, RR; Kempler, L; Marshall, NS; Sivam, S; Williams, SC; Wong, KK; Yee, BJ, 2014) |
"Armodafinil was found to improve simulated driving performance in OSA patients with EDS prior to initiation of CPAP." | 2.78 | Effects of armodafinil on simulated driving and self-report measures in obstructive sleep apnea patients prior to treatment with continuous positive airway pressure. ( Feldman, N; Kay, GG, 2013) |
" In addition, the ratios and associated 90% CIs for Cmax (137 [1." | 2.75 | Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study. ( D'Andrea, DM; Darwish, M; Hellriegel, ET; Kirby, M; Robertson, P; Yang, R, 2010) |
"Armodafinil was well tolerated." | 2.73 | Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. ( Arora, S; Black, JE; Hirshkowitz, M; Niebler, G; Roth, T; Wesnes, K, 2007) |
"Modafinil was well tolerated." | 2.73 | Effect of adjunctive modafinil on wakefulness and quality of life in patients with excessive sleepiness-associated obstructive sleep apnoea/hypopnoea syndrome: a 12-month, open-label extension study. ( Black, J; Hirshkowitz, M, 2007) |
"Daytime symptoms resulting from obstructive sleep apnea (OSA) include impaired neurobehavioural performance and increased sleepiness." | 2.73 | The effect of modafinil following acute CPAP withdrawal: a preliminary study. ( Grunstein, RR; Leung, S; Marshall, NS; Rogers, NL; Starmer, GA; Williams, SC, 2008) |
"Many patients with obstructive sleep apnea (OSA) experience excessive daytime sleepiness (EDS), which can negatively affect daily functioning, cognition, mood, and other aspects of well-being." | 2.72 | Excessive Daytime Sleepiness in Obstructive Sleep Apnea. Mechanisms and Clinical Management. ( Bae, CJ; Lal, C; Strohl, KP; Weaver, TE, 2021) |
"Armodafinil was also associated with significantly reduced interference of ES with daily activities and global fatigue." | 2.72 | Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. ( Arora, S; Black, J; Niebler, G; Roth, T; Schmidt-Nowara, W; Wesnes, KA; White, D, 2006) |
"Some patients with obstructive sleep apnea/hypopnea syndrome (OSA/HS) who are regular users of nasal continuous positive airway pressure (nCPAP) therapy continue to experience daytime sleepiness that impairs performance and quality of life." | 2.71 | Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP. ( Dinges, DF; Weaver, TE, 2003) |
"Modafinil remained effective and well tolerated as an adjunct therapy for residual daytime sleepiness even after 12 weeks of daily dosing in patients with OSA receiving nCPAP therapy." | 2.71 | Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study. ( Erman, MK; Hirshkowitz, M; Schmidt-Nowara, W; Schwartz, JR, 2003) |
"Modafinil was generally well tolerated and did not adversely affect nighttime sleep or nCPAP use." | 2.71 | Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. ( Black, JE; Hirshkowitz, M, 2005) |
"Patients with obstructive sleep apnea/hypopnea syndrome can experience residual daytime sleepiness despite regular use of nasal continuous positive airway pressure therapy." | 2.70 | Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. ( Black, JE; Matheson, JK; Pack, AI; Schwartz, JR, 2001) |
"Modafinil is a nonamphetamine nootropic drug with an increasingly therapeutic interest due to its different sites of action and behavioral effects in comparison to cocaine or amphetamine." | 2.66 | Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects. ( Dinis-Oliveira, RJ; Sousa, A, 2020) |
"Collapsibility of the upper airway in obstructive sleep apnea (OSA) causes repeated arousals from sleep, decreased oxygen saturation of the blood, and excessive sleepiness (ES)." | 2.45 | Optimal treatment of obstructive sleep apnea and excessive sleepiness. ( Doghramji, P; Rosenberg, R, 2009) |
"Clinical trials in these sleep disorders demonstrated an enhanced efficacy for wake promotion (wake sustained for a longer time period using doses lower than those of modafinil)." | 2.44 | Armodafinil for excessive daytime sleepiness. ( Nishino, S; Okuro, M, 2008) |
"Modafinil also has the potential for interactions with other drugs metabolised via cytochrome P450 enzyme pathways." | 2.43 | Modafinil: new indications for wake promotion. ( Schwartz, JR, 2005) |
"Modafinil (Provigil is a wake-promoting agent that is pharmacologically distinct from CNS stimulants, such as amfetamine, dexamfetamine and methylphenidate." | 2.43 | Modafinil : a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder. ( Keating, GM; Raffin, MJ, 2005) |
"A significant number of patients with obstructive sleep apnea neither tolerate positive airway pressure (PAP) therapy nor achieve successful outcomes from either upper airway surgeries or use of an oral appliance." | 2.43 | Medical therapy for obstructive sleep apnea: a review by the Medical Therapy for Obstructive Sleep Apnea Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine. ( Ballard, RD; Guilleminault, C; Magalang, UJ; Sanders, MH; Strohl, KP; Veasey, SC, 2006) |
"OSA can induce excessive daytime sleepiness (EDS) and is associated with impaired cognition and anxiety." | 1.91 | Recovery Mimicking "Ideal" CPAP Adherence Does Not Improve Wakefulness or Cognition in Chronic Murine Models of OSA: Effect of Wake-Promoting Agents. ( Badran, M; Barrow, MB; Gozal, D; Puech, C; Runion, AR, 2023) |
"BACKGROUND Obstructive sleep apnea-hypopnea syndrome (OSAHS) is characterized by repeated episodes of reduction in airflow due to the collapse of the upper airway during sleep." | 1.48 | Comparison of the Efficacy, Side Effects, and Cost of Modafinil and Intranasal Mometasone Furoate in Obstructive Sleep Apnea-Hypopnea Syndrome: A Preliminary Clinical Study. ( Duan, Z; Fu, J; Zhang, S, 2018) |
"In modafinil-treated patients, clinically significant increases in diastolic or systolic blood pressure were infrequent (n = 9 and n = 1, respectively, < 1% of patients)." | 1.34 | Evaluation of the safety of modafinil for treatment of excessive sleepiness. ( Arora, S; Dayno, JM; Erman, MK; Hirshkowitz, M; Roth, T; Schwartz, JR, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 29 (46.77) | 29.6817 |
2010's | 23 (37.10) | 24.3611 |
2020's | 10 (16.13) | 2.80 |
Authors | Studies |
---|---|
Puech, C | 3 |
Badran, M | 3 |
Barrow, MB | 3 |
Runion, AR | 3 |
Gozal, D | 3 |
Pitre, T | 1 |
Mah, J | 1 |
Roberts, S | 1 |
Desai, K | 1 |
Gu, Y | 1 |
Ryan, C | 1 |
Busse, JW | 1 |
Zeraatkar, D | 1 |
Sousa, A | 1 |
Dinis-Oliveira, RJ | 1 |
Lin, YC | 1 |
Chen, TY | 1 |
Chien, WC | 1 |
Chung, CH | 1 |
Chang, HA | 1 |
Kao, YC | 1 |
Tsai, CS | 1 |
Lin, CS | 1 |
Tzeng, NS | 1 |
Javaheri, S | 2 |
Lal, C | 1 |
Weaver, TE | 3 |
Bae, CJ | 1 |
Strohl, KP | 2 |
Ronnebaum, S | 1 |
Bron, M | 1 |
Patel, D | 1 |
Menno, D | 1 |
Bujanover, S | 1 |
Kratochvil, D | 1 |
Lucas, E | 1 |
Stepnowsky, C | 1 |
Krief, S | 1 |
Berrebi-Bertrand, I | 1 |
Nagmar, I | 1 |
Giret, M | 1 |
Belliard, S | 1 |
Perrin, D | 1 |
Uguen, M | 1 |
Robert, P | 1 |
Lecomte, JM | 1 |
Schwartz, JC | 1 |
Finance, O | 1 |
Ligneau, X | 1 |
Zhang, S | 1 |
Fu, J | 1 |
Duan, Z | 1 |
Carr, ZJ | 1 |
Vells, B | 1 |
Wood, BR | 1 |
Lowery, JD | 1 |
Rogers, AM | 1 |
Kunselman, AA | 1 |
Karamchandani, K | 1 |
Vaida, SJ | 1 |
Kay, GG | 1 |
Feldman, N | 3 |
Herring, WJ | 1 |
Liu, K | 1 |
Hutzelmann, J | 1 |
Snavely, D | 1 |
Snyder, E | 1 |
Ceesay, P | 1 |
Lines, C | 1 |
Michelson, D | 1 |
Roth, T | 5 |
Inoue, Y | 1 |
Takasaki, Y | 1 |
Yamashiro, Y | 1 |
Launois, SH | 1 |
Tamisier, R | 1 |
Lévy, P | 1 |
Pépin, JL | 1 |
Chapman, JL | 2 |
Kempler, L | 1 |
Chang, CL | 1 |
Williams, SC | 3 |
Sivam, S | 1 |
Wong, KK | 1 |
Yee, BJ | 2 |
Grunstein, RR | 3 |
Marshall, NS | 4 |
Greve, DN | 1 |
Duntley, SP | 1 |
Larson-Prior, L | 1 |
Krystal, AD | 1 |
Diaz, MT | 1 |
Drummond, SP | 1 |
Thein, SG | 1 |
Kushida, CA | 1 |
Yang, R | 3 |
Thomas, RJ | 1 |
Mayer, G | 1 |
Benes, H | 1 |
Young, P | 1 |
Bitterlich, M | 1 |
Rodenbeck, A | 1 |
Sukhal, S | 1 |
Khalid, M | 1 |
Tulaimat, A | 1 |
Wang, D | 1 |
Bai, XX | 1 |
Hua, SC | 1 |
Kim, JW | 1 |
D'Rozario, A | 1 |
Vakulin, A | 1 |
Hedner, J | 1 |
Kuan, YC | 1 |
Wu, D | 1 |
Huang, KW | 1 |
Chi, NF | 1 |
Hu, CJ | 1 |
Chung, CC | 1 |
Tam, KW | 1 |
Huang, YH | 1 |
West, SD | 1 |
Lochmüller, H | 1 |
Hughes, J | 1 |
Atalaia, A | 1 |
Marini-Bettolo, C | 1 |
Baudouin, SV | 1 |
Anderson, KN | 1 |
Nishino, S | 1 |
Okuro, M | 1 |
Ballard, RD | 2 |
Rosenberg, R | 1 |
Doghramji, P | 1 |
Garnock-Jones, KP | 1 |
Dhillon, S | 1 |
Scott, LJ | 1 |
George, CF | 2 |
Inhaber, N | 2 |
Steininger, TL | 2 |
Grzeschik, SM | 2 |
Lai, C | 2 |
Zheng, Y | 2 |
Castriotta, RJ | 1 |
Atanasov, S | 1 |
Wilde, MC | 1 |
Masel, BE | 1 |
Lai, JM | 1 |
Kuna, ST | 1 |
Chasens, ER | 1 |
Arora, S | 5 |
Black, W | 1 |
Hoey, P | 1 |
Mayze, T | 1 |
Dopp, JM | 1 |
Morgan, BJ | 1 |
Schwartz, JR | 5 |
Khan, A | 1 |
McCall, WV | 1 |
Weintraub, J | 1 |
Tiller, J | 2 |
Black, JE | 4 |
Hull, SG | 1 |
Harsh, JR | 1 |
Darwish, M | 1 |
Kirby, M | 1 |
D'Andrea, DM | 1 |
Hellriegel, ET | 1 |
Robertson, P | 1 |
Andrade, C | 1 |
Black, J | 3 |
Ault, A | 1 |
Dinges, DF | 1 |
Hirshkowitz, M | 5 |
Erman, MK | 2 |
Schmidt-Nowara, W | 2 |
Douglas, NJ | 1 |
Lieberman, JA | 1 |
Keating, GM | 1 |
Raffin, MJ | 1 |
White, D | 1 |
Wesnes, KA | 1 |
Niebler, G | 2 |
Wesnes, K | 1 |
Veasey, SC | 1 |
Guilleminault, C | 2 |
Sanders, MH | 1 |
Magalang, UJ | 1 |
Carl, D | 1 |
Sica, DA | 1 |
Valentino, RM | 1 |
Foldvary-Schaefer, N | 1 |
Rippon, GA | 1 |
Nikolaou, A | 1 |
Schiza, SE | 1 |
Giakoumaki, SG | 1 |
Roussos, P | 1 |
Siafakas, N | 1 |
Bitsios, P | 1 |
Dayno, JM | 1 |
Bittencourt, LR | 1 |
Lucchesi, LM | 1 |
Rueda, AD | 1 |
Garbuio, SA | 1 |
Palombini, LO | 1 |
Tufik, S | 1 |
Rogers, NL | 1 |
Leung, S | 1 |
Starmer, GA | 1 |
Lankford, DA | 1 |
Pack, AI | 1 |
Matheson, JK | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase IIa, Randomized, Double-blind, Placebo-controlled, 3-period Crossover, Adaptive Dose Design, Clinical Trial to Evaluate Safety & Efficacy of MK0249 in Treating Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea[NCT00620659] | Phase 2 | 125 participants (Actual) | Interventional | 2008-02-29 | Terminated | ||
Double-Blind, Placebo-Controlled, Functional Neuroimaging Study of Armodafinil (200 mg/Day) on Prefrontal Cortical Activation in Patients With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea[NCT00711516] | Phase 4 | 40 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
Improvement in Sleep Symptomatology and Neurocognitive Function Using Photobiomodulation in Post-Concussion Patients With Sleep-Wake Disturbances[NCT05072743] | 20 participants (Anticipated) | Interventional | 2021-10-20 | Recruiting | |||
A Randomized, Double Blind, Placebo Controlled Evaluation of Modafinil vs Placebo for the Treatment of General Anesthesia Related Delayed Emergence in Patients With the Diagnosis of Obstructive Sleep Apnea[NCT02494102] | Phase 4 | 105 participants (Actual) | Interventional | 2016-02-29 | Terminated | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Clinical Global Impressions Scale of Severity (CGI-S) is a subscale of the CGI which is a standard psychometric scale used to demonstrate changes and improvements in illness. CGI-S consists of a 7-point scale rated from 1 to 7. The investigator or sponsor-approved clinician judged how ill the patient was with respect to Excessive Daytime Sleepiness (EDS) at the time of the CGI-S rating (CGIS-EDS), with higher scores indicating more severe illness. (NCT00620659)
Timeframe: At Week 2
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo | 3.76 |
MK0249 Mode Dose | 3.43 |
"The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire that provides subjective reports that equate with sleep propensity, not with 'subjective sleepiness'. Having a high sleep propensity means having a history of dozing in situations that have a relatively low soporific nature, in which normal subjects seldom doze. The ESS consists of eight items, which are rated from 0 (would never dose) to 3 (high chance of dozing). The ESS score is the total score of the 8 individual items; this total score ranges from 0 to 24 (higher total score is worse)." (NCT00620659)
Timeframe: At Week 2
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo | 12.81 |
MK0249 Mode Dose | 10.83 |
The Maintenance of Wakefulness Test (MWT) is an objective assessment of sleepiness that measures the ability of a patient to remain awake. The primary endpoint was the mean of sleep latency (average of the first 4 MWTs which were at 0900, 1100, 1300, and 1500), where latency for each MWT was defined as the time to onset of the first 16 continuous seconds of any stage of sleep; if no sleep was observed according to these rules, then latency was defined as 30 minutes. The comparison was for the mode dose of MK0249 versus modafinil. (NCT00620659)
Timeframe: At Week 2
Intervention | Minutes (Least Squares Mean) |
---|---|
MK0249 Mode Dose | 13.34 |
Modafinil 200 mg | 17.45 |
The Maintenance of Wakefulness Test (MWT) is an objective assessment of sleepiness that measures the ability of a patient to remain awake. The primary endpoint was the mean of sleep latency (average of the first 4 MWTs which were at 0900, 1100, 1300, and 1500), where latency for each MWT was defined as the time to onset of the first 16 continuous seconds of any stage of sleep; if no sleep was observed according to these rules, then latency was defined as 30 minutes. The comparison was for the mode dose of MK0249 versus placebo. (NCT00620659)
Timeframe: At Week 2
Intervention | Minutes (Least Squares Mean) |
---|---|
Placebo | 12.79 |
MK0249 Mode Dose | 13.34 |
The Maintenance of Wakefulness Test (MWT) is an objective assessment of sleepiness that measures the ability of a patient to remain awake. The primary endpoint was the mean of sleep latency (average of the first 4 MWTs which were at 0900, 1100, 1300, and 1500), where latency for each MWT was defined as the time to onset of the first 16 continuous seconds of any stage of sleep; if no sleep was observed according to these rules, then latency was defined as 30 minutes. The comparison was for the top 2 doses pooled of MK0249 versus modafinil. (NCT00620659)
Timeframe: At Week 2
Intervention | Minutes (Least Squares Mean) |
---|---|
MK0249 Top 2 Doses Pooled | 13.64 |
Modafinil 200 mg | 17.45 |
With this outcome measure the correlation between the BOLD signal intensity on fMRI in the ACC versus performance on the 2-back working memory test was evaluated for both Armodafinil and Placebo. Correlation coefficients and P-values are presented for each treatment group. (NCT00711516)
Timeframe: Week 2 or Last Observation after Baseline
Intervention | Correlation Coefficient (Number) |
---|---|
Armodafinil | 0.025 |
Placebo | -0.012 |
With this outcome measure the correlation between the number of voxels activated on fMRI (voxels that differ significantly from reference wave form) in PPC versus performance on the 2-back working memory test was evaluated for both Armodafinil and Placebo. Correlation coefficients and P-values are presented for each treatment group. (NCT00711516)
Timeframe: Week 2 or Last Observation after Baseline
Intervention | Correlation Coefficient (Number) |
---|---|
Armodafinil | 0.355 |
Placebo | -0.358 |
With this outcome measure the correlation between the number of voxels activated on fMRI (voxels that differ significantly from reference wave form) in the thalamus versus performance on the 2-back working memory test was evaluated for both Armodafinil and Placebo. Correlation coefficients and P-values are presented for each treatment group. (NCT00711516)
Timeframe: Week 2 or Last Observation after Baseline
Intervention | Correlation Coefficient (Number) |
---|---|
Armodafinil | 0.405 |
Placebo | -0.038 |
With this outcome measure the correlation between the number of voxels activated on fMRI (voxels that differ significantly from reference wave form) in ACC versus performance on the 2-back working memory test was evaluated for both Armodafinil and Placebo. Correlation coefficients and P-values are presented for each treatment group. (NCT00711516)
Timeframe: Week 2 or Last Observation after Baseline
Intervention | Correlation Coefficient (Number) |
---|---|
Armodafinil | 0.254 |
Placebo | -0.152 |
With this outcome measure the correlation between the BOLD signal intensity on fMRI over DLPFC versus performance on the 2-back working memory test was evaluated for both Armodafinil and Placebo. Correlation coefficients and P-values are presented for each treatment group. (NCT00711516)
Timeframe: Week 2 or Last Observation after Baseline
Intervention | Correlation Coefficient (Number) |
---|---|
Armodafinil | -0.122 |
Placebo | 0.789 |
With this outcome measure the correlation between the number of voxels activated on fMRI (voxels that differ significantly from reference wave form) in DLPFC versus performance on the 2-back working memory test was evaluated for both Armodafinil and Placebo. Correlation coefficients and P-values are presented for each treatment group. (NCT00711516)
Timeframe: Endpoint (Week 2 or last observation after baseline)
Intervention | Correlation Coefficient (Number) |
---|---|
Armodafinil | 0.422 |
Placebo | -0.445 |
With this outcome measure the correlation between the BOLD signal intensity on fMRI in PPC versus performance on the 2-back working memory test was evaluated for both Armodafinil and Placebo. Correlation coefficients and P-values are presented for each treatment group. (NCT00711516)
Timeframe: Week 2 or Last Observation after Baseline
Intervention | Correlation Coefficient (Number) |
---|---|
Armodafinil | 0.065 |
Placebo | 0.364 |
With this outcome measure the correlation between BOLD signal intensity on fMRI in the thalamus versus performance on the 2-back working memory test was evaluated for both Armodafinil and Placebo. Correlation coefficients and P-values are presented for each treatment group. (NCT00711516)
Timeframe: Week 2 or Last Observation after Baseline
Intervention | Correlation Coefficient (Number) |
---|---|
Armodafinil | -0.029 |
Placebo | 0.582 |
Functional magnetic resonance imaging (fMRI) is a brain imaging technique that identifies neuronal activation in regions related to specific tasks or sensory stimulation such as language, vision, hearing, and short-term memory. When neuronal activity increases, blood flow increases to that part of the brain with an increase in the oxygen content of the blood. Increase in oxygen content causes the fMRI signal in that part of the brain to change, and is the basis of the BOLD effect. The percent change in BOLD signal from Baseline to 2 weeks or last observation after baseline is presented here. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Percent change in BOLD signal (Median) |
---|---|
Armodafinil | -1.777 |
Placebo | 7.148 |
Functional magnetic resonance imaging (fMRI) is a brain imaging technique that identifies neuronal activation in regions related to specific tasks or sensory stimulation such as language, vision, hearing, and short-term memory. When neuronal activity increases, blood flow increases to that part of the brain with an increase in the oxygen content of the blood. Increase in oxygen content causes the fMRI signal in that part of the brain to change, and is the basis of the BOLD effect. The percent change in BOLD signal from Baseline to 2 weeks or last observation after baseline is presented here. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Percentage change in BOLD signal (Median) |
---|---|
Armodafinil | -0.398 |
Placebo | 4.704 |
Functional magnetic resonance imaging (fMRI) is a brain imaging technique that identifies neuronal activation in regions related to specific tasks or sensory stimulation such as language, vision, hearing, and short-term memory. When neuronal activity increases, blood flow increases to that part of the brain with an increase in the oxygen content of the blood. Increase in oxygen content causes the fMRI signal in that part of the brain to change, and is the basis of the BOLD effect. The percent change in BOLD signal from Baseline to 2 weeks or last observation after baseline is presented here. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Percent change in BOLD signal (Median) |
---|---|
Armodafinil | 16.363 |
Placebo | 2.099 |
Functional magnetic resonance imaging (fMRI) is a brain imaging technique that identifies neuronal activation in regions related to specific tasks or sensory stimulation such as language, vision, hearing, and short-term memory. When neuronal activity increases, blood flow increases to that part of the brain with an increase in the oxygen content of the blood. Increase in oxygen content causes the fMRI signal in that part of the brain to change, and is the basis of the BOLD effect. The percent change in BOLD signal from Baseline to 2 weeks or last observation after baseline is presented here. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Percent change in Bold signal (Median) |
---|---|
Armodafinil | 3.199 |
Placebo | -2.021 |
At resting state, this is an analysis of the change from Baseline to Endpoint in the blood oxygen level dependent (BOLD) signal intensity in the posterior parietal cortex (PPC). (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | BOLD signal intensity (Median) |
---|---|
Armodafinil | 2.667 |
Placebo | 2.479 |
"During anatomic scanning (and prior to functional runs when anatomic scanning was not performed), a modified continuous 10 minute attention task (Psychomotor Vigilance Test [PVT]-like task, nearly identical to the PVT but for absence of performance feedback) was run to obtain a measure of vigilance in the scanner-in this instance, the + symbol appeared at random (mean inter trial interval of 5 seconds, range 2 - 10 seconds) but disappeared when subject pressed a button. Subject performance speed was measured. Change in subject performance speed from Baseline to Endpoint is presented." (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after Baseline)
Intervention | milliseconds (ms) (Least Squares Mean) |
---|---|
Armodafinil | -31.9 |
Placebo | -6.8 |
The 2-Back is a verbal working memory test in which random letters are presented visually every 4 sec, with each stimulus lasting 500 msec. Subjects are asked to make a yes/no response following each letter indicating whether it was the same or different from the letter presented two earlier. The load on working memory was the ordering, retention, updating, and manipulation of 2 letters and consideration of the relationship to a 3rd newly presented letter, which could have been a target or a nontarget. The change from baseline in response latency at endpoint is presented here. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Milliseconds (ms) (Mean) |
---|---|
Armodafinil | 2.3 |
Placebo | -59.0 |
The primary outcome was the change from baseline in number of contiguous activated voxels in the dorsolateral prefrontal cortex (DLPFC) on functional magnetic resonance imaging (fMRI) at Week 2(or last observation after baseline). Each voxel is compared to the reference wave form. If it differs from that value p<0.05, the voxel is considered active. fMRI is a brain imaging technique that identifies neuronal activation related to specific tasks or sensory stimulation. Increased neuronal activity increases blood flow and oxygen content to the activated part of the brain, altering fMRI signal. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Activated voxels (Mean) |
---|---|
Armodafinil | -1932.3 |
Placebo | -2428.1 |
At resting state, this is an analysis of the change from Baseline to Endpoint in the blood oxygen level dependent signal (BOLD) intensity in the anterior cingulate cortex (ACC). (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after Baseline)
Intervention | BOLD signal intensity (Median) |
---|---|
Armodafinil | 2.778 |
Placebo | 0.0 |
At resting state, this is an analysis of the change from Baseline to Endpoint in the blood oxygen level dependent (BOLD) signal intensity in the dorsolateral prefrontal cortex (DLPFC). (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | BOLD signal intensity (Median) |
---|---|
Armodafinil | 5.556 |
Placebo | 3.755 |
At resting state, this is an analysis of the change from Baseline to Endpoint in the blood oxygen level dependent (BOLD) signal intensity in the thalamus. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after Baseline)
Intervention | BOLD signal intensity (Median) |
---|---|
Armodafinil | 5.128 |
Placebo | 1.429 |
The outcome was the change from baseline in number of contiguous activated voxels in the anterior cingulate cortex (ACC) on functional magnetic resonance imaging (fMRI) at Week 2(or last observation after baseline). Each voxel is compared to the reference wave form. If it differs from that value p<0.05, the voxel is considered active. fMRI is a brain imaging technique that identifies neuronal activation related to specific tasks or sensory stimulation. Increased neuronal activity increases blood flow and oxygen content to the activated part of the brain, altering fMRI signal. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Activated Voxels (Mean) |
---|---|
Armodafinil | -107.3 |
Placebo | -206.5 |
The outcome was the change from baseline in number of contiguous activated voxels in the thalamus on functional magnetic resonance imaging (fMRI) at Week 2(or last observation after baseline). Each voxel is compared to the reference wave form. If it differs from that value significantly (p<0.05), the voxel is considered active. fMRI is a brain imaging technique that identifies neuronal activation related to specific tasks or sensory stimulation. Increased neuronal activity increases blood flow and oxygen content to the activated part of the brain, altering fMRI signal. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Activated voxels (Mean) |
---|---|
Armodafinil | -841.7 |
Placebo | -1417.9 |
The outcome was the change from baseline in number of contiguous activated voxels in the posterior parietal cortex (PPC) on functional magnetic resonance imaging (fMRI) at Week 2(or last observation after baseline). Each voxel is compared to the reference wave form. If it differs from that value with p<0.05, the voxel is considered active. fMRI is a brain imaging technique that identifies neuronal activation related to specific tasks or sensory stimulation. Increased neuronal activity increases blood flow and oxygen content to the activated part of the brain, altering fMRI signal. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Activated voxels (Mean) |
---|---|
Armodafinil | -595.0 |
Placebo | -773.3 |
At resting state, this is an analysis of the change from Baseline to Endpoint in the number of contiguous activated voxels meeting pre-defined threshold (voxels that differ significantly from reference wave form) on functional magnetic resonance imaging (fMRI) in the anterior cingulate cortex (ACC). (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after Baseline)
Intervention | Voxels (Median) |
---|---|
Armodafinil | -27.5 |
Placebo | -54.0 |
At resting state, this is an analysis of the change from Baseline to Endpoint in the number of activated voxels meeting predefined threshold (voxels that differ significantly from reference wave form) on functional magnetic resonance imaging (fMRI) in the posterior parietal cortex (PPC). (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after Baseline)
Intervention | Voxels (Median) |
---|---|
Armodafinil | 22.0 |
Placebo | 104.3 |
At resting state, this is an analysis of the change from Baseline to Endpoint in the number of contiguous activated voxels (voxels that differ significantly from reference wave form) on functional magnetic resonance imaging (fMRI) in the dorsolateral prefrontal cortex. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Voxels (Median) |
---|---|
Armodafinil | 941.5 |
Placebo | -174.5 |
At resting state, this is an analysis of the change from Baseline to Endpoint in the number of activated voxels meeting predefined threshold (voxels that differ significantly from reference wave form) on functional magnetic resonance imaging (fMRI) in the thalamus. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Voxels (Median) |
---|---|
Armodafinil | -621.0 |
Placebo | -883.8 |
Severity of sleepiness, was assessed by the Clinical Global Impression of Severity (CGI-S) at Baseline. The clinician assessed the change from baseline in the patient's condition, as related to excessive sleepiness, in response to treatment using the CGI-C, which consisted of the following 7 categories and scoring assignments: very much improved, much improved, minimally improved, no change, minimally worse, much worse, and very much worse. Responders had to be at least minimally improved from Baseline to qualify as a responder at Endpoint. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Participants (Number) |
---|---|
Armodafinil | 13 |
Placebo | 9 |
The patient's evaluation of excessive daytime sleepiness was measured by the patient reported measure, ESS (Johns1991). The ESS score was based on responses to questions referring to 8 everyday situations (eg, sitting and reading, talking to someone, being stopped in traffic) and reflected a patient's propensity to fall asleep in those situations. The ESS score was derived from the sum of the values from questions corresponding to the 8 situations. Scores for the ESS ranged from 0 to 24, with a higher score indicating a greater daytime sleepiness. Change from baseline to endpoint is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil | -5.8 |
Placebo | -2.9 |
This is a subgroup analysis of responders on the 2-back working memory test for the number of activated voxels (that differ significantly from reference wave form) in Anterior Cingulate Cortex (ACC). A responder in the 2-back working memory test was defined as a patient showing a response latency of less than 713 ms at endpoint. This is based on baseline data from the matched control population in a functional imaging study in patients with obstructive sleep apnea. The change from Baseline to Endpoint in the number of activated voxels for each treatment group among the responders is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Voxels (Mean) |
---|---|
Armodafinil | -38.6 |
Placebo | -227.8 |
This is a subgroup analysis of non-responders on the 2-back working memory test for the number of voxels meeting the predefined threshold (voxels that differ significantly from reference wave form) on functional magnetic resonance imaging (fMRI). A non-responder in the 2-back working memory test was defined as a patient showing a response latency of 713 ms or greater at endpoint. The change from Baseline to Endpoint in the number of activated voxels in the anterior cingulate cortex (ACC)for each treatment group among the non-responders is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Voxels (Mean) |
---|---|
Armodafinil | -153.1 |
Placebo | -199.4 |
This is a subgroup analysis of non-responders on the 2-back working memory test for the number of voxels meeting the predefined threshold (voxels that differ significantly from reference wave form) on functional magnetic resonance imaging (fMRI). A non-responder in the 2-back working memory test was defined as a patient showing a response latency of 713 ms or greater at endpoint. The change from Baseline to Endpoint in the number of activated voxels in the dorsolateral prefrontal cortex (DLPFC)for each treatment group among the non-responders is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Voxels (Mean) |
---|---|
Armodafinil | -2279.4 |
Placebo | -2784.4 |
This is a subgroup analysis of responders on the 2-back working memory test for the number of voxels meeting the predefined threshold in DLPFC. A responder in the 2-back working memory test was defined as a patient showing a response latency of less than 713 ms at endpoint. This is based on baseline data from the matched control population in a functional imaging study in patients with obstructive sleep apnea. The change from Baseline to Endpoint in the number of activated voxels (that differ significantly from reference wave form) for each treatment group among the responders is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Activated voxels (Mean) |
---|---|
Armodafinil | -1411.6 |
Placebo | -1359.0 |
This is a subgroup analysis of non-responders on the 2-back working memory test for the number of voxels meeting the predefined threshold (voxels that differ significantly from reference wave form) on functional magnetic resonance imaging (fMRI). A non-responder in the 2-back working memory test was defined as a patient showing a response latency of 713 ms or greater at endpoint. The change from Baseline to Endpoint in the number of activated voxels in the posterior parietal cortex (PPC)for each treatment group among the non-responders is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Voxels (Mean) |
---|---|
Armodafinil | -465.5 |
Placebo | -898.5 |
This is a subgroup analysis of responders on the 2-back working memory test for the number of voxels (voxels that differ significantly from reference wave form) in Posterior Parietal Cortex (PPC). A responder in the 2-back working memory test was defined as a patient showing a response latency of less than 713 ms at endpoint. This is based on baseline data from the matched control population in a functional imaging study in patients with obstructive sleep apnea. The change from Baseline to Endpoint in the number of activated voxels for each treatment group among the responders is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Voxels (Mean) |
---|---|
Armodafinil | -789.1 |
Placebo | -397.7 |
This is a subgroup analysis of non-responders on the 2-back working memory test for the number of voxels meeting the predefined threshold (voxels that differ significantly from reference wave form) on functional magnetic resonance imaging (fMRI). A non-responder in the 2-back working memory test was defined as a patient showing a response latency of 713 ms or greater at endpoint. The change from Baseline to Endpoint in the number of activated voxels in the thalamus for each treatment group among the non-responders is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Voxels (Mean) |
---|---|
Armodafinil | -893.1 |
Placebo | -1408.3 |
This is a subgroup analysis of responders on the 2-back working memory test for the number of activated voxels (voxels that differ significantly from reference wave form) in the thalamus. A responder in the 2-back working memory test was defined as a patient showing a response latency of less than 713 ms at endpoint. This is based on baseline data from the matched control population in a functional imaging study in patients with obstructive sleep apnea. The change from Baseline to Endpoint in the number of activated voxels for each treatment group among the responders is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Voxels (Mean) |
---|---|
Armodafinil | -764.7 |
Placebo | -1446.7 |
OTS is a spatial planning test based on the Tower of London and the CANTAB Stockings of Cambridge test, and measures frontal lobe function. Patient shown 2 displays containing 3 colored balls and a row of boxes containing numbers. The patient is shown one demonstration problem and then solves 3 additional problems (easy). Problems increased in complexity, from one to six moves. With additional problems (hard) the patient has to work out how many moves the solutions required in their heads. Mean change from Baseline to endpoint in number of choices to correct for easy problems is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Choices to correct (Mean) |
---|---|
Armodafinil | 0.0 |
Placebo | 0.0 |
OTS is a spatial planning test based on the Tower of London and the CANTAB Stockings of Cambridge test, and measures frontal lobe function. Patient shown 2 displays containing 3 colored balls and a row of boxes containing numbers. The patient was shown one demonstration problem and then solves 3 additional problems (easy). Problems increased in complexity, from one to six moves. With additional problems (hard) the patient had to work out how many moves the solutions required in their heads. Mean change from baseline to endpoint in number of choices to correct for hard problems is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Choices to correct (Mean) |
---|---|
Armodafinil | -0.2 |
Placebo | 0.0 |
OTS is a spatial planning test based on Tower of London test and the CANTAB Stockings of Cambridge test, and measures frontal lobe function. Subject is shown 2 displays containing 3 colored balls and a row of boxes containing numbers. The patient was shown one demonstration problem and then had to solve 3 additional problems (easy). The problems increased in complexity, from one to six moves. With additional problems subject had to work out how many moves the solutions required in their heads (hard). Change from baseline to endpoint in Mean correct latency for the easy problems is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Milliseconds (ms) (Mean) |
---|---|
Armodafinil | -787.9 |
Placebo | -666.7 |
OTS is a spatial planning test based on Tower of London test and the CANTAB Stockings of Cambridge test, and measures frontal lobe function. Subject is shown 2 displays containing 3 colored balls and a row of boxes containing numbers. The patient was shown one demonstration problem and then had to solve 3 additional problems (easy). The problems increased in complexity, from one to six moves. With additional problems subject had to work out how many moves the solutions required in their heads (hard). Change from baseline to endpoint in Mean correct latency for the hard problems is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Milliseconds (ms) (Mean) |
---|---|
Armodafinil | -733.3 |
Placebo | -6898.1 |
"The PRM test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) assesses episodic memory as measured by a patient's ability to encode and recognize visual information. Patterns appear sequentially on the screen, and patients are instructed to remember them. Twenty minutes following the immediate recognition test, another delayed recognition test is performed, featuring the same stimuli as in the first phase. The change from baseline to endpoint in percent correct responses of this delayed test are presented here. Subjects complete 24 trials per assessment." (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Percent correct trials (Mean) |
---|---|
Armodafinil | 0.4 |
Placebo | -1.1 |
The PRM test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) assesses episodic memory by a patient's ability to encode and recognize visual information. Patterns appear sequentially on the screen, and patients are instructed to remember them. Immediately afterwards a recognition test is performed, in which each pattern shown earlier is presented with another pattern of similar form and color. Patient has to touch the pattern seen earlier. Change from baseline to endpoint in % correct responses with immediate recall is presented. Subjects complete 24 trials per assessment. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Percent correct trials (Mean) |
---|---|
Armodafinil | -0.1 |
Placebo | 3.2 |
The RTI is a measure of simple and choice reaction time, movement time and spatio-temporal vigilance during simple and 5 choice reaction time trials. This task also permits measurement of anticipatory/premature responding and perseverative responding. The patient responded to a yellow spot appearing on the screen by letting go of the press pad and touching the location in which the spot appeared. The yellow spot appeared in any 1 of 5 locations in the 5 choice reaction time phase. The change from baseline to endpoint in median correct latency is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Milliseconds (ms) (Median) |
---|---|
Armodafinil | -6.5 |
Placebo | -12.5 |
The RTI is a measure of simple and choice reaction time, movement time and spatio-temporal vigilance during simple and 5 choice reaction time trials. This task also permits measurement of anticipatory/premature responding and perseverative responding. The patient responded to a yellow spot appearing on the screen by letting go of the press pad and touching the location in which the spot appeared. The yellow spot appeared in a single location during the simple reaction time phase. The change from baseline to endpoint in median correct latency is presented here. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Milliseconds (ms) (Median) |
---|---|
Armodafinil | -13.5 |
Placebo | -4.5 |
"The MOS-CF6 is an instrument to assess patient self-reported cognitive function. Items were selected to cover 6 relevant aspects of cognitive functioning as follows: confusion, concentration/thinking, attention, memory, reasoning, problem solving, and processing speed. The CF 6 item responses include 6 choices, ranging from none of the time to all of the time. The CF-6 was scored by summing responses across the 6 items and converting the total to a 0 to 100 point scale, with higher scores indicating better cognitive functioning. Change in MOS-CF6 from baseline to endpoint is reported." (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil | 6.1 |
Placebo | -0.2 |
Length of time of above compared between groups (NCT02494102)
Timeframe: 24 hours
Intervention | minutes (Mean) |
---|---|
Placebo | 53.5 |
Modafinil | 61.0 |
Postanesthesia quality recovery scale (PQRS). Component and aggregate scoring on the scale. Measures physiology, nociceptive, emotional activities of daily living cognitive and overall patient perspective. The scale is dimensionless and the aggregate of all individually tested dimensions is scaled from 17-65. A higher value implies improved postanesthesia recovery. Mean difference was assessed in each patient and aggregated thus patients with no difference between pre- and post-operative scores were zeroed (received a zero score if the difference was zero). A negative value was associated with worse outcome. (NCT02494102)
Timeframe: baseline and 6 hours after surgery
Intervention | units on a scale (Mean) |
---|---|
Placebo | -5.67 |
Modafinil | -8.91 |
21 reviews available for modafinil and Apnea, Obstructive Sleep
Article | Year |
---|---|
Comparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea : A Systematic Review and Network Meta-analysis.
Topics: Autoreceptors; Disorders of Excessive Somnolence; Humans; Modafinil; Network Meta-Analysis; Sleep Ap | 2023 |
Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects.
Topics: Anxiety; Diarrhea; Drug Eruptions; Drug Interactions; Erythema Multiforme; Forensic Sciences; Headac | 2020 |
Update on Persistent Excessive Daytime Sleepiness in OSA.
Topics: Carbamates; Disorders of Excessive Somnolence; Humans; Modafinil; Phenylalanine; Piperidines; Sleep | 2020 |
Excessive Daytime Sleepiness in Obstructive Sleep Apnea. Mechanisms and Clinical Management.
Topics: Continuous Positive Airway Pressure; Disorders of Excessive Somnolence; Humans; Modafinil; Quality o | 2021 |
Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea.
Topics: Benzhydryl Compounds; Carbamates; Disorders of Excessive Somnolence; Double-Blind Method; Humans; Mo | 2021 |
On treatment but still sleepy: cause and management of residual sleepiness in obstructive sleep apnea.
Topics: Benzhydryl Compounds; Continuous Positive Airway Pressure; Depression; Disorders of Excessive Somnol | 2013 |
Effect of Wakefulness-Promoting Agents on Sleepiness in Patients with Sleep Apnea Treated with CPAP: A Meta-Analysis.
Topics: Benzhydryl Compounds; Continuous Positive Airway Pressure; Disorders of Excessive Somnolence; Humans | 2015 |
Modafinil/armodafinil in obstructive sleep apnoea: a systematic review and meta-analysis.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Pressure; | 2016 |
Effects of Modafinil and Armodafinil in Patients With Obstructive Sleep Apnea: A Meta-analysis of Randomized Controlled Trials.
Topics: Benzhydryl Compounds; Humans; Modafinil; Randomized Controlled Trials as Topic; Sleep; Sleep Apnea, | 2016 |
Armodafinil for excessive daytime sleepiness.
Topics: Animals; Benzhydryl Compounds; Central Nervous System Stimulants; Humans; Modafinil; Narcolepsy; Sle | 2008 |
Management of patients with obstructive sleep apnea.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Pressure; Fatigu | 2008 |
Optimal treatment of obstructive sleep apnea and excessive sleepiness.
Topics: Age Factors; Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Pre | 2009 |
Armodafinil.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Clinical Trials as Topic; Humans; Modafinil | 2009 |
Pharmacologic approaches for the management of symptoms and cardiovascular consequences of obstructive sleep apnea in adults.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Central Nervous System Stimulants; Combined Modality | 2010 |
Managing excessive daytime sleepiness in adults.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Dextroamphetamine; Disorders of Exce | 2004 |
Modafinil: new indications for wake promotion.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Clinical Trials as Topic; Disorders of Exce | 2005 |
Modafinil : a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder.
Topics: Animals; Benzhydryl Compounds; Central Nervous System Stimulants; Disorders of Excessive Somnolence; | 2005 |
Medical therapy for obstructive sleep apnea: a review by the Medical Therapy for Obstructive Sleep Apnea Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine.
Topics: Benzhydryl Compounds; Combined Modality Therapy; Continuous Positive Airway Pressure; Evidence-Based | 2006 |
Obstructive sleep apnea, hypertension, and wakefulness-promoting agents.
Topics: Benzhydryl Compounds; Blood Pressure; Central Nervous System Stimulants; Circadian Rhythm; Heart Rat | 2007 |
Modafinil in the treatment of excessive daytime sleepiness.
Topics: Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulan | 2007 |
Armodafinil: a new treatment for excessive sleepiness.
Topics: Animals; Benzhydryl Compounds; Central Nervous System Stimulants; Drug and Narcotic Control; Drugs, | 2008 |
26 trials available for modafinil and Apnea, Obstructive Sleep
Article | Year |
---|---|
Solriamfetol enhances wakefulness and improves cognition and anxiety in a murine model of OSA.
Topics: Animals; Anxiety; Cognition; Disease Models, Animal; Disorders of Excessive Somnolence; Male; Mice; | 2023 |
A double blind randomized placebo controlled pilot study of single-dose preoperative modafinil for functional recovery after general anesthesia in patients with obstructive sleep apnea.
Topics: Aged; Airway Extubation; Anesthesia Recovery Period; Anesthesia, General; Benzhydryl Compounds; Bloo | 2018 |
Effects of armodafinil on simulated driving and self-report measures in obstructive sleep apnea patients prior to treatment with continuous positive airway pressure.
Topics: Adult; Automobile Driving; Benzhydryl Compounds; Computer Simulation; Continuous Positive Airway Pre | 2013 |
Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study.
Topics: Adolescent; Adult; Benzhydryl Compounds; Combined Modality Therapy; Continuous Positive Airway Press | 2013 |
Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study.
Topics: Adult; Aged; Benzhydryl Compounds; Combined Modality Therapy; Continuous Positive Airway Pressure; D | 2013 |
Modafinil improves daytime sleepiness in patients with mild to moderate obstructive sleep apnoea not using standard treatments: a randomised placebo-controlled crossover trial.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Cross-Over Studies; Disorders of Excessive Somnolence | 2014 |
Effect of armodafinil on cortical activity and working memory in patients with residual excessive sleepiness associated with CPAP-Treated OSA: a multicenter fMRI study.
Topics: Adolescent; Adult; Benzhydryl Compounds; Cerebral Cortex; Continuous Positive Airway Pressure; Disor | 2014 |
Modafinil in the treatment of idiopathic hypersomnia without long sleep time--a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Benzhydryl Compounds; Double-Blind Method; Female; Humans; Idiopathic Hypersomnia | 2015 |
Modafinil Increases Awake EEG Activation and Improves Performance in Obstructive Sleep Apnea during Continuous Positive Airway Pressure Withdrawal.
Topics: Attention; Automobile Driving; Benzhydryl Compounds; Biomarkers; Continuous Positive Airway Pressure | 2015 |
A safety trial of sodium oxybate in patients with obstructive sleep apnea: Acute effects on sleep-disordered breathing.
Topics: Adjuvants, Anesthesia; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Comorbi | 2010 |
Treatment of sleep disorders after traumatic brain injury.
Topics: Adult; Benzhydryl Compounds; Benzothiazoles; Brain Injuries; Central Nervous System Stimulants; Diso | 2009 |
A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome.
Topics: Adjuvants, Anesthesia; Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Combined Moda | 2011 |
Modafinil improves functional outcomes in patients with residual excessive sleepiness associated with CPAP treatment.
Topics: Activities of Daily Living; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Co | 2009 |
Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month, open-label, flexible-dose study with an extension period.
Topics: Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Female; Follow-Up Studies; Hea | 2010 |
The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study.
Topics: Adult; Benzhydryl Compounds; Blood Pressure; Central Nervous System Stimulants; Double-Blind Method; | 2010 |
Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study.
Topics: Area Under Curve; Benzhydryl Compounds; Central Nervous System Stimulants; Cross-Over Studies; Disor | 2010 |
Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP.
Topics: Adult; Aged; Arousal; Attention; Benzhydryl Compounds; Continuous Positive Airway Pressure; Double-B | 2003 |
Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study.
Topics: Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Chemotherapy, Adjuvant; Contin | 2003 |
Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positiv | 2005 |
Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Pressure; Disord | 2006 |
Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Attention; Benzhydryl Compounds; Central Nervous System Stimul | 2007 |
Effect of adjunctive modafinil on wakefulness and quality of life in patients with excessive sleepiness-associated obstructive sleep apnoea/hypopnoea syndrome: a 12-month, open-label extension study.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Pressure; Double | 2007 |
The 5-min pupillary alertness test is sensitive to modafinil: a placebo controlled study in patients with sleep apnea.
Topics: Adult; Arousal; Benzhydryl Compounds; Body Mass Index; Central Nervous System Stimulants; Circadian | 2008 |
Placebo and modafinil effect on sleepiness in obstructive sleep apnea.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Combined Modality Therapy; Comorbidity; Con | 2008 |
The effect of modafinil following acute CPAP withdrawal: a preliminary study.
Topics: Adult; Arousal; Attention; Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Posit | 2008 |
Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea.
Topics: Adult; Aged; Analysis of Variance; Benzhydryl Compounds; Central Nervous System Stimulants; Combined | 2001 |
15 other studies available for modafinil and Apnea, Obstructive Sleep
Article | Year |
---|---|
Solriamfetol improves chronic sleep fragmentation-induced increases in sleep propensity and ameliorates explicit memory in male mice.
Topics: Animals; Disorders of Excessive Somnolence; Male; Mice; Mice, Inbred C57BL; Modafinil; Sleep; Sleep | 2023 |
Recovery Mimicking "Ideal" CPAP Adherence Does Not Improve Wakefulness or Cognition in Chronic Murine Models of OSA: Effect of Wake-Promoting Agents.
Topics: Animals; Cognition; Continuous Positive Airway Pressure; Disease Models, Animal; Disorders of Excess | 2023 |
Stimulants associated with reduced risk of hospitalization for motor vehicle accident injury in patients with obstructive sleep apnea-a nationwide cohort study.
Topics: Accidents, Traffic; Adult; Aged; Central Nervous System Stimulants; Databases, Factual; Female; Hosp | 2020 |
Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Amphetamine; Animals; Carbamates; Corp | 2021 |
Comparison of the Efficacy, Side Effects, and Cost of Modafinil and Intranasal Mometasone Furoate in Obstructive Sleep Apnea-Hypopnea Syndrome: A Preliminary Clinical Study.
Topics: Administration, Intranasal; Adult; Benzhydryl Compounds; Female; Humans; Male; Modafinil; Mometasone | 2018 |
Sleepiness and Sleep-related Breathing Disorders in Myotonic Dystrophy and Responses to Treatment: A Prospective Cohort Study.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Cohort Studies; Comorbidity; Continuous Positive Airw | 2016 |
Modafinil use in patients with a primary psychiatric illness.
Topics: Adult; Affect; Arousal; Benzhydryl Compounds; Bipolar Disorder; Brain Injury, Chronic; Central Nervo | 2010 |
Can any medication relieve sleep apnea?
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Humans; Middle Aged; Modafinil; Patient Edu | 2012 |
Modafinil and armodafinil in schizophrenia.
Topics: Antipsychotic Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Cytochrome P-450 CYP1 | 2012 |
Pro: modafinil has a role in management of sleep apnea.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Controlled Clinical Trials as Topic; Female | 2003 |
Narcolepsy drug could be approved for wider use.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Drug Approval; Humans; Modafinil; Narcoleps | 2003 |
Modafinil and sleepiness.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Pressure; Humans | 2003 |
Treatment of patients with obstructive sleep apnea.
Topics: Accidents; Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Press | 2005 |
Armodafinil improves wakefulness and long-term episodic memory in nCPAP-adherent patients with excessive sleepiness associated with obstructive sleep apnea.
Topics: Adult; Attention; Benzhydryl Compounds; Central Nervous System Stimulants; Cognition Disorders; Comb | 2008 |
Evaluation of the safety of modafinil for treatment of excessive sleepiness.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Pressure; | 2007 |